GoodRx (GDRX) 10-Q 12 Nov 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 09, 2020
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Registrant Name	GoodRx Holdings, Inc.
Entity Central Index Key	0001809519
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	false
Entity Shell Company	false
Entity File Number	001-39549
Entity Tax Identification Number	47-5104396
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	233 Wilshire Blvd.
Entity Address, Address Line Two	Suite 990
Entity Address, City or Town	Santa Monica
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90401
City Area Code	855
Local Phone Number	268-2822
Trading Symbol	GDRX
Title of 12(b) Security	Class A Common Stock, $0.0001 par value per share
Security Exchange Name	NASDAQ
Document Quarterly Report	true
Document Transition Report	false
Class A Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		43,925,062
Class B Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		346,357,135

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 1,075,024	$ 26,050
Restricted cash	2,900
Accounts receivable, net	63,518	48,129
Prepaid expenses and other current assets	39,630	12,403
Total current assets	1,181,072	86,582
Property and equipment, net	16,757	1,860
Goodwill	261,116	236,225
Intangible assets, net	39,225	21,267
Capitalized software, net	15,400	5,178
Operating lease right-of-use assets	29,318	32,315
Deferred tax assets, net	1,687	2,207
Other assets	2,230	1,162
Total assets	1,546,805	386,796
Current liabilities
Accounts payable	14,014	7,851
Accrued expenses and other current liabilities	36,093	15,556
Current portion of debt	7,029	7,029
Operating lease liabilities, current	3,029	2,937
Total current liabilities	60,165	33,373
Debt, net	688,891	663,893
Operating lease liabilities, net of current portion	34,424	37,129
Deferred tax liabilities, net	1,772
Other liabilities	5,144	2,974
Total liabilities	790,396	737,369
Commitments and contingencies (Note 8)
Redeemable convertible preferred stock, $0.006 par value; zero and 130,000 shares authorized at September 30, 2020 and December 31, 2019, respectively; and zero and 126,046 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively		737,009
Stockholders' equity (deficit)
Preferred stock, $0.0001 par value; 50,000 and zero shares authorized at September 30, 2020 and December 31, 2019, respectively; and zero shares issued and outstanding at September 30, 2020 and December 31, 2019
Additional paid-in capital	1,848,549	8,788
Accumulated deficit	(1,092,179)	(1,096,830)
Total stockholders' equity (deficit)	756,409	(1,087,582)
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)	1,546,805	386,796
Common Stock
Stockholders' equity (deficit)
Common stock		460
Total stockholders' equity (deficit)		$ 460
Class A and Class B Common Stock
Stockholders' equity (deficit)
Common stock	39
Total stockholders' equity (deficit)	$ 39

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Redeemable convertible preferred stock, par value	$ 0.006	$ 0.006
Redeemable convertible preferred stock, shares authorized	0	130,000,000
Redeemable convertible preferred stock, shares issued	0	126,046,000
Redeemable convertible preferred stock, shares outstanding	0	126,046,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	50,000,000	0
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common Stock
Common stock, par value	$ 0.002	$ 0.002
Common stock, shares authorized	0	380,000,000
Common stock, shares issued	0	229,750,000
Common stock, shares outstanding	0	229,750,000
Common Class A
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	2,000,000,000	0
Common stock, shares issued	42,922,000	0
Common stock, shares outstanding	42,922,000	0
Common Class B
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,000,000,000	0
Common stock, shares issued	346,357,000	0
Common stock, shares outstanding	346,357,000	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue	$ 140,453	$ 101,745	$ 397,156	$ 274,968
Costs and operating expenses:
Cost of revenue, exclusive of depreciation and amortization presented separately below	7,540	3,396	20,383	9,420
Product development and technology	15,846	7,844	38,133	19,480
Sales and marketing	65,113	44,950	180,195	122,639
General and administrative	108,479	4,102	120,698	10,165
Depreciation and amortization	5,160	3,609	14,026	9,355
Total costs and operating expenses	202,138	63,901	373,435	171,059
Operating (loss) income	(61,685)	37,844	23,721	103,909
Other expense (income):
Other expense (income), net	1	(4)	(20)	(3)
Interest income	(24)	(271)	(140)	(580)
Interest expense	6,264	12,773	21,697	39,452
Total other expense, net	6,241	12,498	21,537	38,869
(Loss) income before income tax expense	(67,926)	25,346	2,184	65,040
Income tax benefit (expense)	17,894	(5,727)	2,467	(14,219)
Net (loss) income	(50,032)	19,619	4,651	50,821
Net (loss) income attributable to common stockholders
Basic	(50,032)	12,616	3,045	32,638
Diluted	$ (50,032)	$ 12,708	$ 3,092	$ 32,858
(Loss) earnings per share:
(Loss) earnings per share - basic	$ (0.21)	$ 0.06	$ 0.01	$ 0.14
(Loss) earnings per share - diluted	$ (0.21)	$ 0.05	$ 0.01	$ 0.14
Weighted average shares used in computing (loss) earnings per share:
Basic	241,061	227,058	233,727	226,251
Diluted	241,061	231,770	244,529	230,559
Cost of Sales
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	$ 57		$ 98
Research and Development Expense
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	2,958	$ 449	4,772	$ 1,265
Selling and Marketing Expense
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	4,284	331	5,762	931
General and Administrative Expense
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	$ 99,574	$ 176	$ 100,572	$ 496

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Total	Initial Public Offering	Private Placement	Redeemable Convertible Preferred Stock	Common Stock	Class A and Class B Common Stock	Class A and Class B Common StockInitial Public Offering	Common Class APrivate Placement	Common Class B	Additional Paid-in Capital	Additional Paid-in CapitalInitial Public Offering	Additional Paid-in CapitalPrivate Placement	Accumulated Deficit
Redeemable convertible preferred stock, Beginning balance at Dec. 31, 2018				$ 737,009
Redeemable convertible preferred stock, Beginning balance, Shares at Dec. 31, 2018				126,046,000
Beginning balance at Dec. 31, 2018	$ (1,162,427)				$ 451								$ (1,162,878)
Beginning balance, Shares at Dec. 31, 2018					225,201,000
Stock options exercised	264				$ 1					$ 263
Stock options exercised, Shares					340,000
Stock-based compensation	887									887
Net income (loss)	11,552												11,552
Redeemable convertible preferred stock, Ending balance at Mar. 31, 2019				$ 737,009
Redeemable convertible preferred stock, Ending balance, Shares at Mar. 31, 2019				126,046,000
Ending balance at Mar. 31, 2019	(1,149,724)				$ 452					1,150			(1,151,326)
Ending balance, Shares at Mar. 31, 2019					225,541,000
Redeemable convertible preferred stock, Beginning balance at Dec. 31, 2018				$ 737,009
Redeemable convertible preferred stock, Beginning balance, Shares at Dec. 31, 2018				126,046,000
Beginning balance at Dec. 31, 2018	(1,162,427)				$ 451								(1,162,878)
Beginning balance, Shares at Dec. 31, 2018					225,201,000
Net income (loss)	50,821
Redeemable convertible preferred stock, Ending balance at Sep. 30, 2019				$ 737,009
Redeemable convertible preferred stock, Ending balance, Shares at Sep. 30, 2019				126,046,000
Ending balance at Sep. 30, 2019	(1,104,351)				$ 460					7,246			(1,112,057)
Ending balance, Shares at Sep. 30, 2019					229,449,000
Redeemable convertible preferred stock, Beginning balance at Mar. 31, 2019				$ 737,009
Redeemable convertible preferred stock, Beginning balance, Shares at Mar. 31, 2019				126,046,000
Beginning balance at Mar. 31, 2019	(1,149,724)				$ 452					1,150			(1,151,326)
Beginning balance, Shares at Mar. 31, 2019					225,541,000
Stock options exercised	1,623				$ 3					1,620
Stock options exercised, Shares					1,377,000
Restricted stock issuance					$ 3					(3)
Restricted stock issuance, Shares					1,879,000
Stock-based compensation	1,057									1,057
Net income (loss)	19,650												19,650
Redeemable convertible preferred stock, Ending balance at Jun. 30, 2019				$ 737,009
Redeemable convertible preferred stock, Ending balance, Shares at Jun. 30, 2019				126,046,000
Ending balance at Jun. 30, 2019	(1,127,394)				$ 458					3,824			(1,131,676)
Ending balance, Shares at Jun. 30, 2019					228,797,000
Stock options exercised	729				$ 1					728
Stock options exercised, Shares					379,000
Stock-based compensation	1,072									1,072
Issuance of common stock	1,623				$ 1					1,622
Issuance of common stock, Shares					273,000
Net income (loss)	19,619												19,619
Redeemable convertible preferred stock, Ending balance at Sep. 30, 2019				$ 737,009
Redeemable convertible preferred stock, Ending balance, Shares at Sep. 30, 2019				126,046,000
Ending balance at Sep. 30, 2019	(1,104,351)				$ 460					7,246			(1,112,057)
Ending balance, Shares at Sep. 30, 2019					229,449,000
Redeemable convertible preferred stock, Beginning balance at Dec. 31, 2019	$ 737,009			$ 737,009
Redeemable convertible preferred stock, Beginning balance, Shares at Dec. 31, 2019	126,046,000			126,046,000
Beginning balance at Dec. 31, 2019	$ (1,087,582)				$ 460					8,788			(1,096,830)
Beginning balance, Shares at Dec. 31, 2019					229,750,000
Stock options exercised	692				$ 1					691
Stock options exercised, Shares					467,000
Stock-based compensation	2,501									2,501
Net income (loss)	27,346												27,346
Redeemable convertible preferred stock, Ending balance at Mar. 31, 2020				$ 737,009
Redeemable convertible preferred stock, Ending balance, Shares at Mar. 31, 2020				126,046,000
Ending balance at Mar. 31, 2020	(1,057,043)				$ 461					11,980			(1,069,484)
Ending balance, Shares at Mar. 31, 2020					230,217,000
Redeemable convertible preferred stock, Beginning balance at Dec. 31, 2019	$ 737,009			$ 737,009
Redeemable convertible preferred stock, Beginning balance, Shares at Dec. 31, 2019	126,046,000			126,046,000
Beginning balance at Dec. 31, 2019	$ (1,087,582)				$ 460					8,788			(1,096,830)
Beginning balance, Shares at Dec. 31, 2019					229,750,000
Net income (loss)	$ 4,651
Redeemable convertible preferred stock, Ending balance, Shares at Sep. 30, 2020	0
Ending balance at Sep. 30, 2020	$ 756,409					$ 39				1,848,549			(1,092,179)
Ending balance, Shares at Sep. 30, 2020						389,279,000
Redeemable convertible preferred stock, Beginning balance at Mar. 31, 2020				$ 737,009
Redeemable convertible preferred stock, Beginning balance, Shares at Mar. 31, 2020				126,046,000
Beginning balance at Mar. 31, 2020	(1,057,043)				$ 461					11,980			(1,069,484)
Beginning balance, Shares at Mar. 31, 2020					230,217,000
Stock options exercised	531				$ 1					530
Stock options exercised, Shares					222,000
Stock-based compensation	2,440									2,440
Net income (loss)	27,337												27,337
Redeemable convertible preferred stock, Ending balance at Jun. 30, 2020				$ 737,009
Redeemable convertible preferred stock, Ending balance, Shares at Jun. 30, 2020				126,046,000
Ending balance at Jun. 30, 2020	(1,026,735)				$ 462					14,950			(1,042,147)
Ending balance, Shares at Jun. 30, 2020					230,439,000
Stock options exercised	4,292				$ 1					4,291
Stock options exercised, Shares					780,000	453,000
Stock-based compensation	107,825									107,825
Issuance of common stock		$ 886,856	$ 100,000				$ 3				$ 886,853	$ 100,000
Issuance of common stock, Shares							28,615,000	3,030,000
Redeemable convertible preferred stock, Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering				$ (737,009)
Redeemable convertible preferred stock, Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering, Shares				(126,046,000)
Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering	737,009				$ 252					736,757
Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering, Shares					126,046,000
Conversion of common stock into Class B common stock in connection with initial public offering					$ (715)	$ 36				679
Conversion of common stock into Class B common stock in connection with initial public offering, Shares					(357,265,000)				357,265,000
Common stock withheld for tax obligations	(2,806)									(2,806)
Common stock withheld for tax obligations and net settlement, Shares						(85,000)
Vesting of restricted stock units, Shares						1,000
Net income (loss)	$ (50,032)												(50,032)
Redeemable convertible preferred stock, Ending balance, Shares at Sep. 30, 2020	0
Ending balance at Sep. 30, 2020	$ 756,409					$ 39				$ 1,848,549			$ (1,092,179)
Ending balance, Shares at Sep. 30, 2020						389,279,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities
Net income	$ 4,651	$ 50,821
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	14,026	9,355
Amortization of debt issuance costs	2,430	2,545
Non-cash operating lease expense	3,431	1,497
Stock-based compensation	111,204	2,692
Change in fair value of contingent consideration	901
Deferred income taxes	2,292	26
Changes in operating assets and liabilities, net of effect of business acquisitions
Accounts receivable	(10,928)	(8,013)
Prepaid expenses and other assets	(31,832)	(181)
Accounts payable	3,411	1,461
Accrued expenses and other current liabilities	13,763	7,956
Operating lease liabilities	1,641	(1,454)
Other liabilities	1,501	66
Net cash provided by operating activities	116,491	66,771
Cash flows from investing activities
Purchase of property and equipment	(15,681)	(992)
Acquisitions, net of cash acquired	(55,793)	(31,306)
Capitalized software	(10,333)	(2,987)
Net cash used in investing activities	(81,807)	(35,285)
Cash flows from financing activities
Proceeds from issuance of common stock in initial public offering, net of underwriting discounts and commissions	891,793
Proceeds from private placement	100,000
Proceeds from long-term debt	28,000
Payments on long-term debt	(5,272)	(10,088)
Payment of debt issuance costs	(1,306)
Issuance of common stock		1,623
Payments of initial public offering issuance costs	(1,840)
Proceeds from exercise of stock options	5,148	2,065
Proceeds from early exercise of stock options	667
Net cash provided by (used in) financing activities	1,017,190	(6,400)
Net change in cash, cash equivalents and restricted cash	1,051,874	25,086
Cash, cash equivalents and restricted cash
Beginning of period	26,050	34,600
End of period	1,077,924	59,686
Non cash investing and financing activities
Offering costs included in accounts payable and accrued expenses and other current liabilities	3,097
Right-of-use assets obtained in exchange for new operating lease liabilities	234	3,444
Stock-based compensation included in capitalized software development costs	1,562	324
Capitalized software development costs in accrued expenses and other current liabilities	1,175	417
Employee tax withholding obligations on stock option exercises included in accrued expenses and other current liabilities	2,439
Conversion of preferred stock to common stock in connection with initial public offering	737,009
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	1,075,024	59,686
Restricted cash	2,900
End of period	$ 1,077,924	$ 59,686

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2020
Description Of Business [Abstract]
Description of Business	1. Description of Business GoodRx Holdings, Inc. (the “Company”) and its subsidiaries offer information and tools to help consumers compare prices and save on their prescription drug purchases. The Company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through GoodRx codes that can be used to save money on prescriptions across the United States (the “prescription offering”). The services are free to consumers and the Company primarily earns revenue from its core business from Pharmacy Benefit Managers (“PBMs”) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. The Company also offers other healthcare products and services, including telehealth services. The Company was incorporated in September 2015. On October 7, 2015, the Company acquired 100% of the outstanding shares of GoodRx, Inc. (“GoodRx”). GoodRx was initially formed in September 2011 as GoodRx, Inc., a Delaware corporation. Initial Public Offering The Company’s registration statement on Form S-1 (“IPO Registration Statement”) related to its initial public offering (“IPO”) was declared effective on September 22, 2020, and the Company’s Class A common stock began trading on the Nasdaq Global Select Market on September 23, 2020. On September 25, 2020, the Company completed its IPO of 39,807,691 shares of the Company Class A common stock, $0.0001 par value per share (the “Class A Common Stock”) at an offering price of $33.00 per share, pursuant to the Company’s IPO Registration Statement. The Company sold 28,615,034 shares, including 5,192,307 shares that were sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, and certain existing stockholders sold an aggregate of 11,192,657 shares. The Company received aggregate net proceeds of $886.9 million after deducting underwriting discounts and commissions of $52.5 million and other offering expenses of $4.9 million, $3.1 million of which was unpaid at September 30, 2020. Immediately prior to the completion of the IPO, 126,045,531 outstanding shares of redeemable convertible preferred stock with a carrying value of $737.0 million converted into an equivalent number of shares of common stock. Immediately prior to the completion of the IPO, the Company filed an Amended and Restated Certificate of Incorporation, which authorized a total of 2,000,000,000 shares of Class A Common Stock, 1,000,000,000 shares of Class B Common Stock, $0.0001 par value per share and 50,000,000 shares of Preferred Stock, par value $0.0001 per share (the “Preferred Stock”). Upon the filing of the Amended and Restated Certificate of Incorporation, 357,265,256 shares of the Company’s common stock then outstanding were automatically reclassified into an equivalent number of shares of the Company’s Class B Common Stock. Immediately after the reclassification and prior to the completion of the IPO, a total of 10,098,121 shares of Class B Common Stock held by certain existing shareholders were exchanged for an equivalent number of shares of Class A Common Stock pursuant to terms of certain exchange agreements. As a result, following the completion of the IPO, the Company has two classes of authorized and outstanding common stock: Class A Common Stock and Class B Common Stock. The rights of the holders of the Class A and Class B Common Stock are identical except for voting and conversion rights. The holders of the Class A Common Stock are entitled to one vote per share and the holders of the Class B Common Stock are entitled to 10 votes per share. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at any time at the option of the holder and will automatically convert to Class A Common Stock upon any transfer, except for certain permitted transfers. All Class B Common Stock will convert automatically into an equivalent number of Class A Common Stock upon the earlier of (i) September 25, 2027; and (ii) the first date the aggregate number of shares of Class B Common Stock cease to represent at least 10% of the aggregate outstanding shares of common stock. On September 13, 2020, the Company entered into a stock purchase agreement with an existing investor to issue $100.0 million worth of shares of Class A Common Stock, with the price per share to be equal to the per share price to the public in the Company’s initial public offering of Class A Common Stock. Closing of the investment was subject to certain customary conditions, including the closing of the initial public offering of Class A common stock. Concurrent with the completion of the IPO, the Company issued 3,030,303 shares of Class A Common Stock.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2.Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial information. Certain information and disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements for the year ended December 31, 2019 and the related notes, which are included in the Company's Prospectus dated September 22, 2020 filed with the SEC pursuant to Rule 424(b) of the Securities Act of 1933, as amended, relating to the Company's IPO Registration Statement. The December 31, 2019 condensed consolidated balance sheet was derived from our audited consolidated financial statements as of that date. The Company’s unaudited interim condensed consolidated financial statements include, in the opinion of management, all adjustments, consisting of normal and recurring items, necessary for the fair statement of the condensed consolidated financial statements. There have been no significant changes in accounting policies during the three and nine months ended September 30, 2020 from those disclosed in the annual consolidated financial statements for the year ended December 31, 2019 and the related notes. The operating results for the three and nine months ended September 30, 2020 are not necessarily indicative of the results expected for the full year ending December 31, 2020. Principles of Consolidation The consolidated financial statements include the financial statements of GoodRx Holdings, Inc., its wholly owned subsidiaries and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. Intercompany balances and transactions have been eliminated in consolidation. Results of businesses acquired are included in the Company’s consolidated financial statements from their respective dates of acquisition. Consolidation of VIEs The Company evaluates whether an entity in which it has a variable interest is considered a variable interest entity (“VIE”). VIEs are generally entities that have either a total equity investment that is insufficient to permit the entity to finance its activities without additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest (i.e., ability to make significant decisions through voting rights and a right to receive the expected residual returns of the entity or an obligation to absorb the expected losses of the entity). Under the provisions of Accounting Standards Codification (“ASC”) 810, Consolidation, The Company periodically reassesses whether it is the primary beneficiary of a VIE. On April 18, 2019, the Company acquired Sappira, Inc. d.b.a. HeyDoctor (“HeyDoctor”). HeyDoctor provides management and other services to Professional Service Corporations (“PSCs”), which are owned by medical professionals in accordance with certain state laws which restrict the corporate practice of medicine and require medical practitioners to own such entities. The Company determined that the PSCs are VIEs. The Company also determined that it is able to direct the activities of the PSCs that most significantly impact their economic performance and it funds and absorbs all losses of these VIEs resulting in the Company being the primary beneficiary of the PSCs. Accordingly, the Company consolidates the VIEs. Total revenue and net loss for the VIEs were $3.0 million and $(0.3) million, respectively, for the three months ended September 30, 2020. Total revenue and net loss for the VIEs were $6.6 million and $(0.9) million, Segment Reporting and Geographic Information Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker manages the Company on the basis of one operating segment. During the three and nine months ended September 30, 2020 and the three and nine months ended September 30, 2019, all of the Company’s revenue was from customers located in the United States. In addition, at September 30, 2020 and December 31, 2019, all of the Company’s right-of-use assets and property and equipment was in the United States. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, including the accompanying notes. The Company bases its estimates on historical factors, current circumstances, and the experience and judgment of management. The Company evaluates its estimates and assumptions on an ongoing basis. Actual results could differ from those estimates. Significant estimates reflected in the condensed consolidated financial statements include revenue recognition, valuation of intangible assets, useful lives of long-lived assets and capitalized software costs, recovery of long-lived assets and goodwill, assumptions used for purpose of determining stock-based compensation, and income tax reserves, among others. Certain Risks and Concentrations Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents and accounts receivable. The Company maintains cash deposits with several financial institutions in the United States which, at times, may exceed federally insured limits. Cash may be withdrawn or redeemed on demand. The Company believes that the financial institutions that hold its cash are financially sound and, accordingly, minimal credit risk exists with respect to these balances. The Company has not experienced any losses in such accounts. The Company extends credit to its customers based on an evaluation of their ability to pay amounts due under contractual arrangements and generally does not obtain or require collateral. For the three months ended September 30, 2020, four customers accounted for approximately 16%, 13%, 12% and 10% of the Company’s revenue. For the nine months ended September 30, 2020, three customers accounted for approximately 17%, 16% and 11% of the Company’s revenue. For the three months ended September 30, 2019, two customers accounted for approximately 25% and 24% of the Company’s revenue. For the nine months ended September 30, 2019, two customers accounted for 25% and 23% of the Company’s revenue. At September 30, 2020, two customers accounted for 12% and 11% of the Company’s accounts receivable balance. At December 31, 2019, two customers accounted for 17% and 16% of the Company’s accounts receivable. In March 2020, the World Health Organization declared the outbreak of the novel coronavirus disease (“COVID–19”) a pandemic. COVID-19 has spread to almost every country in the world and all 50 states within the United States. The Company’s prescription offering initially experienced a decline in activity as many consumers avoided visiting healthcare professionals and pharmacies in-person, though in recent months activity in the Company’s prescription offering improved. In addition, the Company has experienced a significant increase in demand for the telehealth offerings. The Company only commenced its telehealth offerings following the acquisition of HeyDoctor in April 2019. The full extent to which the outbreak of COVID-19 will impact the Company’s business, results of operations and financial condition is still unknown and will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume. In light of the currently unknown ultimate duration and severity of COVID-19, the Company faces a greater degree of uncertainty than normal in making the judgments and estimates needed to apply significant accounting policies. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of September 30, 2020 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts, the carrying value of the goodwill and other long-lived assets, incentive-based compensation and income taxes. As of the date of these condensed consolidated financial statements, management is not aware of any specific event or circumstance that would require an update to estimates or judgments or a revision to the carrying value of assets or liabilities. However, these estimates and judgments may change as new events occur and additional information is obtained, which may result in changes being recognized in our consolidated financial statements in future periods. Cash, Cash Equivalents and Restricted Cash The Company considers all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash deposits are all in financial institutions in the United States. Cash and cash equivalents consisted primarily of U.S. Treasury Securities money market funds held with an investment bank and cash on deposit. Cash equivalents, consisting of money market funds, of $1,013.5 million and zero at September 30, 2020 and December 31, 2019, respectively, were classified as Level 1 of the fair value hierarchy and valued using quoted market prices in active markets. The Company had no other material financial instruments that were measured at fair value as of September 30, 2020 and December 31, 2019. Restricted cash as of September 30, 2020 represents cash held in an escrow pursuant to terms of the Scriptcycle business combination relating to contingent consideration. Income Taxes The Company calculates income tax expense in interim periods by applying an estimated annual effective tax rate to income (loss) before income taxes and by calculating the tax effect of discrete items recognized during the period. Revenue For the three and nine months ended September 30, 2020 and 2019, revenue comprises the following: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2020 2019 2020 2019 Prescription transactions revenue $ 124,385 $ 95,795 $ 356,950 $ 260,114 Other revenue 16,068 5,950 40,206 14,854 Total revenue $ 140,453 $ 101,745 $ 397,156 $ 274,968 Stock-Based Compensation Compensation cost is allocated to cost of revenue, product development and technology, sales and marketing, and general and administrative expense in the condensed consolidated statements of operations for stock options and restricted stock awards, based on the fair value of these awards at the date of grant. For awards that vest based on continued service, stock-based compensation cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the awards. For awards with performance vesting conditions, stock-based compensation cost is recognized on a graded vesting basis over the requisite service period when it is probable the performance condition will be achieved. The grant date fair value of stock options that contain service or performance conditions is estimated using the Black-Scholes option-pricing model and the grant date fair value of restricted stock awards that contain service or performance conditions is estimated based on the fair value of the Company’s common stock. For awards with market vesting conditions, the fair value is estimated using a Monte Carlo simulation model that incorporates the likelihood of achieving the market condition. Stock-based compensation cost for awards that contain market vesting conditions is recognized on a graded vesting basis over the requisite service period, even if the market condition is not satisfied. For awards that contain service, performance and market vesting conditions, the Company commences recognition of stock-based compensation cost once it is probable that the performance condition will be achieved. If the performance condition is an initial public offering or a change in control event, the performance condition is not probable of being achieved for accounting purposes until the event occurs. Once it is probable that the performance condition will be achieved, the Company recognizes stock-based compensation cost over the remaining requisite service period under a graded vesting model, with a cumulative adjustment for the portion of the service period that occurred for the period prior to the performance condition becoming probable of being achieved. Thereafter, expense is recognized even if the market condition was not or is not achieved, provided the employee continues to satisfy the service condition. Forfeitures are recognized when they occur. Comprehensive Income During the three and nine months ended September 30, 2020 and the three and nine months ended September 30, 2019, other than net income (loss), the Company did not have any other elements of comprehensive income (loss). Recent Accounting Pronouncements As an “emerging growth company”, the Jumpstart Our Business Startups Act, or the JOBS Act, allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use the adoption dates applicable to private companies. As a result, the Company’s financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective date for new or revised accounting standards that are applicable to public companies. Recently adopted accounting pronouncements In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement Recently issued accounting pronouncements - not yet adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Financial Instruments - Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842) (SEC Update), In August 2018, the FASB issued ASU 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract In October 2018, the FASB issued ASU 2018-17, Consolidation (Topic 810): Targeted Improvements to the Related Party Guidance for Variable Interest Entities In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting

Business Combinations

Business Combinations	9 Months Ended
	Sep. 30, 2020
Business Combinations [Abstract]
Business Combinations	3. Business Combinations Scriptcycle, LLC On August 31, 2020, the Company acquired all of the equity interests of Scriptcycle, LLC, (“Scriptcycle”). Scriptcycle specializes in managing prescription programs and primarily partners with regional retail pharmacy chains to provide discount offerings. The purpose of the acquisition is to help expand the Company’s business capabilities, particularly with respect to its prescription offering. The aggregate purchase consideration is $58.3 million, including the estimated fair value of contingent consideration of $0.8 million. The purchase consideration is subject to working capital and other closing adjustments. The maximum amount of contingent consideration payable is $2.9 million subject to the achievement of certain revenue thresholds through January 2021. As of September 30, 2020, the Company estimated the fair value of the contingent consideration was $1.7 million. The change in the fair value of the contingent consideration from the acquisition date through September 30, 2020 was recorded in general and administrative expenses. The fair value of the contingent consideration is measured using Level 3 inputs in the fair value hierarchy. The Company estimated the fair value of the acquisition related contingent consideration using a Monte-Carlo simulation model. The Company applied a discount rate of 5.4% at the acquisition date and 5.3% at September 30, 2020, which captures the risk associated with the contingent consideration. The significant unobservable input used in the fair value measurement of the contingent consideration is forecasted revenue as defined in the purchase agreement. Significant changes in forecasted revenue would result in a significantly higher or lower fair value measurement. Goodwill associated with this acquisition totaled $24.9 million and is primarily related to the expected long-term synergies and other benefits, including the acquired assembled workforce. The acquisition was considered an acquisition of assets for tax purposes and, accordingly, goodwill is expected to be deductible for tax purposes. Unaudited supplemental pro forma financial information for the Scriptcycle acquisition, and the revenue and earnings of Scriptcycle from the acquisition date through September 30, 2020, have not been presented because the effects were not material to the Company’s consolidated financial statements. Sappira Inc. (d.b.a HeyDoctor) Sappira Inc. (d.b.a HeyDoctor) On April 18, 2019, the Company completed its acquisition of 100% of the equity interests in San Francisco, California-based Sappira Inc. (d.b.a HeyDoctor), a privately-held company offering an online application for consultation with physicians. HeyDoctor can be used by patients to obtain prescriptions for various medical afflictions. The Company intends to use HeyDoctor’s technology and service offerings to increase the visits to the GoodRx online platform. The total purchase consideration for the acquisition of HeyDoctor was $14.3 million in cash, of which $1.4 million was placed in escrow for potential breaches of representations and warranties. The escrow amount, net of any claims for such indemnifiable matters, was released from escrow to stockholders of HeyDoctor in October 2020. The goodwill recorded in connection with this acquisition primarily related to the expected long-term synergies and other benefits, including the acquired assembled workforce, from the acquisition. The acquisition was considered a stock acquisition for tax purposes and, accordingly, goodwill is not expected to be deductible for tax purposes. Identifiable intangible assets related to this acquisition totaled $4.2 million, of which $3.1 million was attributable to developed technology, with an estimated useful life of 4 years and $1.1 million was attributable to trademarks and backlog with useful lives ranging from 1 to 7 years. In addition, the Company acquired current assets of $2.1 million and assumed current liabilities of $0.5 million. Unaudited supplemental pro forma financial information for the HeyDoctor acquisition, and the revenue and earnings of HeyDoctor from the acquisition date through September 30, 2020, have not been presented because the effects were not material to the Company’s consolidated financial statements. FocusScript LLC On August 30, 2019, the Company completed the acquisition of certain software assets and the assembled workforce of Creve Coeur, Missouri-based FocusScript LLC (“FocusScript Acquisition”). The Company intends to use the acquired claim routing software to service its customers. The total purchase consideration consisted of $18.7 million in cash. The goodwill recorded in connection with this acquisition primarily related to the expected long-term synergies and other benefits, including the acquired assembled workforce, from the acquisition. Goodwill is deductible for tax purposes. Identifiable intangible assets related to this acquisition totaled $12.2 million, which was attributable to developed technology with an estimated useful life of 4 years. Disclosure of unaudited supplemental pro forma financial information for the FocusScript Acquisition is not practicable given the Company purchased certain assets and assembled workforce for which historical information was not available. In addition, disclosure of revenues and earnings of FocusScript from the acquisition date through September 30, 2020 is not practicable as the FocusScript Acquisition has been integrated into the Company’s operations.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	9 Months Ended
	Sep. 30, 2020
Prepaid Expense And Other Assets Current [Abstract]
Prepaid Expenses and Other Current Assets	4. Prepaid expenses and other current assets Prepaid expenses and other current assets consisted of the following: (in thousands) September 30, 2020 December 31, 2019 Income taxes receivable $ 28,759 $ — Prepaid expenses $ 8,169 $ 5,014 Lease incentive receivable 2,702 7,389 Total prepaid expenses and other current assets $ 39,630 $ 12,403

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2020
Payables And Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	5. Accrued expenses and other current liabilities Accrued expenses and other current liabilities consisted of the following: (in thousands) September 30, 2020 December 31, 2019 Accrued bonus and payroll $ 12,908 $ 3,037 Accrued marketing 11,372 5,820 Deferred revenue 6,911 3,453 Income taxes payable — 1,349 Other accrued expenses 4,902 1,897 Total accrued expenses and other current liabilities $ 36,093 $ 15,556 Of the $3.5 million deferred revenue balance included in the balance sheet at December 31, 2019, $3.3 million was recognized as revenue during the nine months ended September 30, 2020. The Company expects substantially all of the deferred revenue at September 30, 2020 will be recognized as revenue within the next twelve months.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	6. Income Taxes The effective income tax rate for the three and nine months ended September 30, 2020 was 26.3% and (112.8)%, respectively, and for the three and nine months ended September 30, 2019 was 22.6% and 21.9%, respectively. The change in the Company’s effective income tax rate for the three and nine months ended September 30, 2020 compared to three and nine months ended September 30, 2019 was primarily due to tax effects of nondeductible officers’ stock-based compensation expense partially offset by excess tax benefits related to the exercise of stock options. The Company’s effective income tax rate differs from the U.S. Federal statutory rate of 21% primarily due to effects of non-deductible officers’ stock-based compensation expense, and state income taxes partially offset by benefits from research and development tax credits and excess tax benefits from stock-based compensation expense. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was signed into law, featuring significant tax provisions and other measures to assist individuals and businesses impacted by the economic effects of the COVID-19 pandemic. The CARES Act increased the Section 163(j) interest expense deduction limitation from 30% to 50% of adjusted taxable income, provided for the payment deferral of certain Social Security taxes, made a technical correction allowing Qualified Improvement Property to be treated as 15-year property, and included numerous other provisions. The CARES Act increased the Company’s interest expense deduction applicable to the 2019 tax year resulting in a reduction of deferred tax assets and a corresponding reduction in income taxes payable of zero and approximately $2.3 million during the three and nine months ended September 30, 2020, respectively. There were no significant changes to the Company’s unrecognized tax benefits during the nine months ended September 30, 2020, and the Company does not expect to have any significant changes to unrecognized tax benefits through the end of 2020. In 2020, the ownership of the HeyDoctor PSCs were transferred to different medical professionals. The Company's deferred income taxes reflects carryover tax attributes generated by the VIEs available for future utilization. Section 382 of the Internal Revenue Code (“IRC”) limits the utilization of U.S. net operating loss carryforwards (“NOLs”) following a change of control. As the 2020 change in ownership in the PSCs constitutes a change of control, U.S. NOLs from the PSCs will be subject to an annual limitation under IRC Section 382. Any limitation would not be material to the financial statements as a full valuation allowance has been established against the NOLs from the PSCs due to uncertainty regarding their future realization.

Debt

Debt	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Debt	7. Debt The Company's debt balances at September 30, 2020 and December 31, 2019 were as follows: (in thousands) September 30, 2020 December 31, 2019 Principal balance under First Lien Credit Agreement $ 682,883 $ 688,155 Less unamortized debt issuance costs and discounts (14,963 ) (17,233 ) $ 667,920 $ 670,922 Principal balance under Revolving Credit Facility 28,000 — $ 695,920 $ 670,922 In March 2020, the Company borrowed an aggregate of $28.0 million under its line of credit, which is still outstanding as of September 30, 2020. In May 2020, GoodRx, Inc., the Company’s wholly owned subsidiary, as borrower, and GoodRx Intermediate Holdings, LLC, entered into an amendment of its first lien credit agreement (the “First Lien Credit Agreement”) to increase the amount of the line of credit by $60.0 million to a total of $100.0 million. The line of credit matures on October 11, 2024 and bears interest at a rate equal to the LIBO Screen Rate (as defined in the First Lien Credit Agreement) plus a variable margin based on the Company’s most recently determined Net Leverage Ratio (as defined in the First Lien Credit Agreement), ranging from 2.50 to 3.00% on used amounts and 0.25 to 0.50% on unused amounts. The Company incurred lender and third-party costs of $1.3 million related to the amendment which are recorded in other assets. Regulatory authorities that oversee financial markets have announced that after the end of 2021, they would no longer compel banks currently reporting information used to set the LIBO Screen Rate to continue to make rate submissions. As a result, it is possible that beginning in 2022, the LIBO Screen Rate will no longer be available as a reference rate. Under the terms of the Company's First Lien Credit Agreement, in the event of the discontinuance of the LIBO Screen Rate, a mutually agreed-upon alternate benchmark rate will be established to replace the LIBO Screen Rate. The Company and lenders under its First Lien Credit Agreement shall in good faith establish an alternate benchmark rate which places the lenders and the Company in the same economic position that existed immediately prior to the discontinuation of the LIBO Screen Rate. The Company does not anticipate that the discontinuance of the LIBO Screen Rate will materially impact its liquidity or financial position.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Contingent Consideration The Company is subject to a contingent consideration agreement entered into in connection with its acquisition of Scriptcycle. If the acquired business meets predetermined targets, the Company is obligated to make additional cash payments in accordance with the terms of such contingent consideration agreement, see "Note 3. Business Combinations – Scriptcycle, LLC". Legal Contingencies During the normal course of business, the Company may become subject to, and is presently involved in, legal proceedings, claims and litigation. S uch matters are subject to many uncertainties and outcomes are not predictable with assurance. As of September 30, 2020, the Company is not subject to any currently pending legal matters or claims that could have a material adverse effect on its financial position, results of operations, or cash flows should such litigation be resolved unfavorably.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	9. Stock-Based Compensation Stock Options A summary of the stock option activity for the nine months ended September 30, 2020 is as follows, in thousands, except per share amounts and term information: Weighted Weighted Average Weighted Average Remaining Aggregate Average Exercise Contractual Intrinsic Grant Date Shares Price Term Value Fair Value Outstanding at December 31, 2019 16,850 3.82 8.2 years $ 35,043 Granted 5,597 6.20 $ 2.95 Exercised (467 ) 2.91 1,429 Expired / Cancelled / Forfeited (585 ) 4.15 Outstanding at March 31, 2020 21,395 4.46 8.5 years 51,026 Granted 3,541 6.84 $ 3.17 Exercised (222 ) 2.39 926 Expired / Cancelled / Forfeited (673 ) 5.13 Outstanding at June 30, 2020 24,041 4.81 8.4 years 47,750 Granted 881 33.00 $ 16.60 Exercised (1,233 ) 3.48 22,960 Expired / Cancelled / Forfeited (125 ) 5.21 Outstanding at September 30, 2020 23,564 5.93 8.4 years 1,169,173 Exercisable at September 30, 2020 9,544 3.28 7.3 years 499,342 All options outstanding at September 30, 2020 are options to purchase shares of Class A Common Stock. The fair value of option awards issued with service and performance vesting conditions are estimated on the grant date using the Black-Scholes option pricing model. The following table summarizes the assumptions used: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Risk-free interest rate 0.4% 1.4% - 1.6% 0.4% - 1.4% 1.4% - 2.4% Expected term 5.8 - 6.0 years 5.6 - 6.3 years 5.3 - 6.3 years 5.6 - 6.3 years Expected stock price volatility 55% 50% 50% - 62% 50% Dividend yield — — — — Fair value of common stock per share $33.00 $3.88 - $4.69 $5.94 - $33.00 $2.75 - $4.69 For the three and nine months ended September 30, 2020, the stock-based compensation expense related to stock options was $6.8 million and $10.2 million, respectively. For the three and nine months ended September 30, 2019, the stock-based compensation expense related to stock options was $0.7 million and $2.1 million, respectively. At September 30, 2020, there was $40.2 million of total unrecognized stock-based compensation cost related to stock options, excluding stock options which contain performance and market conditions described below, which is expected to be recognized over a weighted-average remaining service period of 3.3 years. In June 2020, the Company granted stock options to purchase 0.6 million shares of common stock at an exercise price of $6.84 per share that vest upon continued service and the achievement of both performance and market conditions. For stock options to purchase 0.4 million shares of common stock, the service condition is satisfied monthly over a 4-year period and for stock options to purchase 0.2 million shares of common stock the service condition is satisfied on January 1, 2022. The performance condition was satisfied upon the closing of the Company’s IPO. The market condition is satisfied upon the Company’s common stock achieving a per share price threshold in the IPO, an average trading price of the Company’s stock for a period subsequent to the IPO, or a per share price in a change in control transaction. For stock options to purchase 0.2 million, 0.2 million and 0.2 million shares of common stock, the per share price thresholds for these market conditions are $17.82, $23.76 and $29.70, respectively, subject to adjustment for stock splits and other similar transactions. The Company estimated the grant date fair value of these awards to be $1.4 million using a Monte Carlo simulation model. The Company recognized $0.3 million of stock-based compensation expense in the three months ended September 30, 2020 related to these options. In June 2020, the Company modified the terms of an option to purchase 0.4 million shares of common stock. The original award that would otherwise have been cancelled upon the employee’s departure from the Company was modified to permit the former employee to only exercise the award within 30 days after the completion of a performance condition, which are the Company completing its IPO or a change in control of the Company or a declaration of dividend payment, as defined. The fair value of this option of $2.4 million on the modification date was recognized as stock-based compensation expense on the effective date of the Company’s IPO. Restricted Stock and Restricted Stock Units (“Restricted Stock”) The following table summarizes Restricted Stock activity for the three and nine months ended September 30, 2020: Restricted Restricted Stock Units for Class A Restricted Stock Units for Class B Weighted Average Stock Common Common Grant Date (in thousands, except per share amounts) Awards Stock Stock Fair Value Nonvested restricted shares at December 31, 2019 1,879 — — $ 3.88 Granted — — — — Vested — — — — Nonvested restricted shares at March 31, 2020 1,879 — — 3.88 Granted — — — — Vested (470 ) — — 3.88 Nonvested restricted shares at June 30, 2020 1,409 — — 3.88 Granted — 948 24,633 22.07 Vested — (1 ) — 33.00 Nonvested restricted shares at September 30, 2020 1,409 947 24,633 21.12 For the three and nine months ended September 30, 2020, total stock-based compensation expense related to Restricted Stock awards was $0.5 million and $1.4 million, respectively. For the three and nine months ended September 30, 2019, the stock-based compensation expense related to Restricted Stock awards was $0.3 million and $0.6 million, respectively. At September 30, 2020, there was $4.6 million of total unrecognized stock-based compensation cost related to these Restricted Stock awards which was expected to be recognized over the remaining service period of 2.6 years due to the earlier than expected achievement of stock price goals, a portion of this unrecognized compensation cost was recognized as compensation expense during the fourth quarter of 2020. See “Note 11. Subseque. In September 2020, the Company granted Restricted Stock Units (“RSUs”) for Class A Common Stock that will substantially vest over a four-year period. For the three and nine months ended September 30, 2020, total stock-based compensation expense related to these RSUs was $1.6 million. At September 30, 2020, there was $29.7 million of total unrecognized stock-based compensation cost related to these RSUs which was expected to be recognized over the remaining service period of 3.9 years. On September 11, 2020, the Board of Directors granted RSUs covering an aggregate of 24,633,066 shares of common stock to the Company’s Co-Chief Executive Officers, subject to the completion of an initial public offering. Each of the Co-Chief Executive Officers received (i) 8,211,022 RSUs that vest based on the achievement of stock price goals ranging from $6.07 per share to $51.28 per share, subject to continued employment through the applicable vesting date (the “Performance-Vesting Founders Awards”) and (ii) 4,105,511 RSUs that vest in equal quarterly installments over four years, subject to continued employment through the applicable vesting date (the “Time-Vesting Founders Awards”). Any Performance-Vesting Founders Awards that vest will be settled in shares of common stock on the third anniversary of the applicable vesting date or, if earlier, upon a qualifying change in control event. The Performance-Vesting Founders Awards and Time-Vesting Founders Awards are subject to certain vesting acceleration terms. The estimated fair value of these awards of $533.3 million is expected to be recognized over a weighted average period of 1.2 years, though could be earlier if the stock price goals are achieved earlier than estimated. During the three months ended September 30, 2020, the Company has recognized a cumulative $98.1 million of stock-based compensation expense, with $10.4 million relating to the Time-Vesting Founders Awards and $87.7 million to the Performance-Vesting Founders Awards. At September 30, 2020, there was $435.2 million of total unrecognized stock-based compensation cost related to these RSUs. Due to the earlier than expected achievement of stock price goals, a portion of this unrecognized stock-based compensation cost was recognized as expense during the fourth quarter of 2020. See “Note 11. Subsequent Events”.

Basic and Diluted Earnings Per

Basic and Diluted Earnings Per Share	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Basic and Diluted Earnings Per Share	10. Basic and diluted earnings per share The Company has two classes of common stock, Class A and Class B. Basic and diluted earnings per share (“EPS”) attributable to common stockholders for Class A and Class B common stock were the same because they are entitled to the same liquidation and dividend rights. The Company computes EPS using the two-class method required for participating securities. The two-class method requires net income to be allocated between common stock and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. In periods where the Company has net losses, losses are not allocated to participating securities as they are not required to fund the losses. The Company considers redeemable convertible preferred stock to be participating securities as preferred stockholders have rights to participate in dividends with the common stockholders. Basic EPS is computed by dividing net income attributable to common stockholders by the weighted average number of common shares outstanding during the period. Weighted average number of common shares outstanding includes contingently issuable shares where there is no circumstance under which those shares would not be issued. The Co-Chief Executives’ Performance-Vesting Founders Awards once vested are settled in shares of common stock on the third anniversary of the applicable vesting date or, if earlier, upon a qualifying change in control event. At the time of vesting, these shares are contingently issuable and included in the weighted average number of common shares outstanding for basic EPS. The Company computes diluted EPS under a two-class method where income is reallocated between common stock, potential common stock and participating securities. Stock-based awards that contain vesting provisions contingent on achievement of performance or market conditions are included in the computation of diluted earnings per share, if dilutive, from the beginning of the period or date of issuance if later, if all necessary conditions to vest have been satisfied during the period. If all conditions have not been met by the end of the period, dilutive EPS includes the number of shares that would be issuable if the end of the period were the end of the contingency period. Potential common stock includes stock options, restricted stock awards, and RSUs computed using the treasury stock method. The computation of earnings (loss) per share for the three and nine months ended September 30, 2020 and 2019 is as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands, except per share data) 2020 2019 2020 2019 Numerator: Net (loss) income $ (50,032 ) $ 19,619 $ 4,651 $ 50,821 Less: Undistributed earnings allocated to convertible preferred stock — (7,003 ) (1,606 ) (18,183 ) Net (loss) income attributable to common stockholders - basic $ (50,032 ) $ 12,616 $ 3,045 $ 32,638 Add: Undistributed earnings reallocated to holders of common stock — 92 47 220 Net (loss) income attributable to common stockholders - diluted $ (50,032 ) $ 12,708 $ 3,092 $ 32,858 Denominator: Weighted average shares - basic 241,061 227,058 233,727 226,251 Dilutive impact of stock options and restricted stock awards — 4,712 10,802 4,308 Weighted average shares - diluted 241,061 231,770 244,529 230,559 (Loss) earnings per share Basic $ (0.21 ) $ 0.06 $ 0.01 $ 0.14 Diluted $ (0.21 ) $ 0.05 $ 0.01 $ 0.14 The following weighted-average potentially dilutive shares were excluded from the computation of diluted net (loss) income per share for the periods presented because including them would have been antidilutive: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2020 2019 2020 2019 Redeemable convertible preferred stock 117,825 126,046 123,285 126,046 Stock options and restricted stock awards 30,537 8,654 7,540 7,503

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	11. Subsequent Events In October 2020, the Company repaid the outstanding balance under its revolving line of credit of $28.0 million. All the stock price goals with respect to the Performance-Vesting Founders Awards, see “Note 9. Stock-based compensation”, were achieved as of October 22, 2020. As a result, all 16,422,044 Performance-Vesting Founders Awards vested, resulting in recognition of approximately $232.1 million of stock-based compensation expense during the fourth quarter of 2020. In October 2020, the Company’s Board of Directors granted RSUs of 1.3 million shares of Class A Common Stock to employees, which will substantially vest over a four-year period. The Company estimates the grant date fair value of these RSUs is approximately $60.9 million, which will be recognized as stock-based compensation cost, net of forfeitures that occur, over approximately four years.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial information. Certain information and disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements for the year ended December 31, 2019 and the related notes, which are included in the Company's Prospectus dated September 22, 2020 filed with the SEC pursuant to Rule 424(b) of the Securities Act of 1933, as amended, relating to the Company's IPO Registration Statement. The December 31, 2019 condensed consolidated balance sheet was derived from our audited consolidated financial statements as of that date. The Company’s unaudited interim condensed consolidated financial statements include, in the opinion of management, all adjustments, consisting of normal and recurring items, necessary for the fair statement of the condensed consolidated financial statements. There have been no significant changes in accounting policies during the three and nine months ended September 30, 2020 from those disclosed in the annual consolidated financial statements for the year ended December 31, 2019 and the related notes. The operating results for the three and nine months ended September 30, 2020 are not necessarily indicative of the results expected for the full year ending December 31, 2020.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the financial statements of GoodRx Holdings, Inc., its wholly owned subsidiaries and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. Intercompany balances and transactions have been eliminated in consolidation. Results of businesses acquired are included in the Company’s consolidated financial statements from their respective dates of acquisition. Consolidation of VIEs The Company evaluates whether an entity in which it has a variable interest is considered a variable interest entity (“VIE”). VIEs are generally entities that have either a total equity investment that is insufficient to permit the entity to finance its activities without additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest (i.e., ability to make significant decisions through voting rights and a right to receive the expected residual returns of the entity or an obligation to absorb the expected losses of the entity). Under the provisions of Accounting Standards Codification (“ASC”) 810, Consolidation, The Company periodically reassesses whether it is the primary beneficiary of a VIE. On April 18, 2019, the Company acquired Sappira, Inc. d.b.a. HeyDoctor (“HeyDoctor”). HeyDoctor provides management and other services to Professional Service Corporations (“PSCs”), which are owned by medical professionals in accordance with certain state laws which restrict the corporate practice of medicine and require medical practitioners to own such entities. The Company determined that the PSCs are VIEs. The Company also determined that it is able to direct the activities of the PSCs that most significantly impact their economic performance and it funds and absorbs all losses of these VIEs resulting in the Company being the primary beneficiary of the PSCs. Accordingly, the Company consolidates the VIEs. Total revenue and net loss for the VIEs were $3.0 million and $(0.3) million, respectively, for the three months ended September 30, 2020. Total revenue and net loss for the VIEs were $6.6 million and $(0.9) million,
Segment Reporting and Geographic Information	Segment Reporting and Geographic Information Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker manages the Company on the basis of one operating segment. During the three and nine months ended September 30, 2020 and the three and nine months ended September 30, 2019, all of the Company’s revenue was from customers located in the United States. In addition, at September 30, 2020 and December 31, 2019, all of the Company’s right-of-use assets and property and equipment was in the United States.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, including the accompanying notes. The Company bases its estimates on historical factors, current circumstances, and the experience and judgment of management. The Company evaluates its estimates and assumptions on an ongoing basis. Actual results could differ from those estimates. Significant estimates reflected in the condensed consolidated financial statements include revenue recognition, valuation of intangible assets, useful lives of long-lived assets and capitalized software costs, recovery of long-lived assets and goodwill, assumptions used for purpose of determining stock-based compensation, and income tax reserves, among others.
Certain Risks and Concentrations	Certain Risks and Concentrations Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents and accounts receivable. The Company maintains cash deposits with several financial institutions in the United States which, at times, may exceed federally insured limits. Cash may be withdrawn or redeemed on demand. The Company believes that the financial institutions that hold its cash are financially sound and, accordingly, minimal credit risk exists with respect to these balances. The Company has not experienced any losses in such accounts. The Company extends credit to its customers based on an evaluation of their ability to pay amounts due under contractual arrangements and generally does not obtain or require collateral. For the three months ended September 30, 2020, four customers accounted for approximately 16%, 13%, 12% and 10% of the Company’s revenue. For the nine months ended September 30, 2020, three customers accounted for approximately 17%, 16% and 11% of the Company’s revenue. For the three months ended September 30, 2019, two customers accounted for approximately 25% and 24% of the Company’s revenue. For the nine months ended September 30, 2019, two customers accounted for 25% and 23% of the Company’s revenue. At September 30, 2020, two customers accounted for 12% and 11% of the Company’s accounts receivable balance. At December 31, 2019, two customers accounted for 17% and 16% of the Company’s accounts receivable. In March 2020, the World Health Organization declared the outbreak of the novel coronavirus disease (“COVID–19”) a pandemic. COVID-19 has spread to almost every country in the world and all 50 states within the United States. The Company’s prescription offering initially experienced a decline in activity as many consumers avoided visiting healthcare professionals and pharmacies in-person, though in recent months activity in the Company’s prescription offering improved. In addition, the Company has experienced a significant increase in demand for the telehealth offerings. The Company only commenced its telehealth offerings following the acquisition of HeyDoctor in April 2019. The full extent to which the outbreak of COVID-19 will impact the Company’s business, results of operations and financial condition is still unknown and will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume. In light of the currently unknown ultimate duration and severity of COVID-19, the Company faces a greater degree of uncertainty than normal in making the judgments and estimates needed to apply significant accounting policies. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts COVID-19 as of September 30, 2020 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts, the carrying value of the goodwill and other long-lived assets, incentive-based compensation and income taxes. As of the date of these condensed consolidated financial statements, management is not aware of any specific event or circumstance that would require an update to estimates or judgments or a revision to the carrying value of assets or liabilities. However, these estimates and judgments may change as new events occur and additional information is obtained, which may result in changes being recognized in our consolidated financial statements in future periods.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash The Company considers all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash deposits are all in financial institutions in the United States. Cash and cash equivalents consisted primarily of U.S. Treasury Securities money market funds held with an investment bank and cash on deposit. Cash equivalents, consisting of money market funds, of $1,013.5 million and zero at September 30, 2020 and December 31, 2019, respectively, were classified as Level 1 of the fair value hierarchy and valued using quoted market prices in active markets. The Company had no other material financial instruments that were measured at fair value as of September 30, 2020 and December 31, 2019. Restricted cash as of September 30, 2020 represents cash held in an escrow pursuant to terms of the Scriptcycle business combination relating to contingent consideration.
Income Taxes	Income Taxes The Company calculates income tax expense in interim periods by applying an estimated annual effective tax rate to income (loss) before income taxes and by calculating the tax effect of discrete items recognized during the period.
Revenue	Revenue For the three and nine months ended September 30, 2020 and 2019, revenue comprises the following: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2020 2019 2020 2019 Prescription transactions revenue $ 124,385 $ 95,795 $ 356,950 $ 260,114 Other revenue 16,068 5,950 40,206 14,854 Total revenue $ 140,453 $ 101,745 $ 397,156 $ 274,968
Stock-Based Compensation	Stock-Based Compensation Compensation cost is allocated to cost of revenue, product development and technology, sales and marketing, and general and administrative expense in the condensed consolidated statements of operations for stock options and restricted stock awards, based on the fair value of these awards at the date of grant. For awards that vest based on continued service, stock-based compensation cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the awards. For awards with performance vesting conditions, stock-based compensation cost is recognized on a graded vesting basis over the requisite service period when it is probable the performance condition will be achieved. The grant date fair value of stock options that contain service or performance conditions is estimated using the Black-Scholes option-pricing model and the grant date fair value of restricted stock awards that contain service or performance conditions is estimated based on the fair value of the Company’s common stock. For awards with market vesting conditions, the fair value is estimated using a Monte Carlo simulation model that incorporates the likelihood of achieving the market condition. Stock-based compensation cost for awards that contain market vesting conditions is recognized on a graded vesting basis over the requisite service period, even if the market condition is not satisfied. For awards that contain service, performance and market vesting conditions, the Company commences recognition of stock-based compensation cost once it is probable that the performance condition will be achieved. If the performance condition is an initial public offering or a change in control event, the performance condition is not probable of being achieved for accounting purposes until the event occurs. Once it is probable that the performance condition will be achieved, the Company recognizes stock-based compensation cost over the remaining requisite service period under a graded vesting model, with a cumulative adjustment for the portion of the service period that occurred for the period prior to the performance condition becoming probable of being achieved. Thereafter, expense is recognized even if the market condition was not or is not achieved, provided the employee continues to satisfy the service condition. Forfeitures are recognized when they occur.
Comprehensive Income	Comprehensive Income During the three and nine months ended September 30, 2020 and the three and nine months ended September 30, 2019, other than net income (loss), the Company did not have any other elements of comprehensive income (loss).
Recent Accounting Pronouncements	Recent Accounting Pronouncements As an “emerging growth company”, the Jumpstart Our Business Startups Act, or the JOBS Act, allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use the adoption dates applicable to private companies. As a result, the Company’s financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective date for new or revised accounting standards that are applicable to public companies. Recently adopted accounting pronouncements In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement Recently issued accounting pronouncements - not yet adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Financial Instruments - Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842) (SEC Update), In August 2018, the FASB issued ASU 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract In October 2018, the FASB issued ASU 2018-17, Consolidation (Topic 810): Targeted Improvements to the Related Party Guidance for Variable Interest Entities In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Revenue	For the three and nine months ended September 30, 2020 and 2019, revenue comprises the following: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2020 2019 2020 2019 Prescription transactions revenue $ 124,385 $ 95,795 $ 356,950 $ 260,114 Other revenue 16,068 5,950 40,206 14,854 Total revenue $ 140,453 $ 101,745 $ 397,156 $ 274,968

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2020
Prepaid Expense And Other Assets Current [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following: (in thousands) September 30, 2020 December 31, 2019 Income taxes receivable $ 28,759 $ — Prepaid expenses $ 8,169 $ 5,014 Lease incentive receivable 2,702 7,389 Total prepaid expenses and other current assets $ 39,630 $ 12,403

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2020
Payables And Accruals [Abstract]
Summary of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following: (in thousands) September 30, 2020 December 31, 2019 Accrued bonus and payroll $ 12,908 $ 3,037 Accrued marketing 11,372 5,820 Deferred revenue 6,911 3,453 Income taxes payable — 1,349 Other accrued expenses 4,902 1,897 Total accrued expenses and other current liabilities $ 36,093 $ 15,556

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Schedule of Debt	The Company's debt balances at September 30, 2020 and December 31, 2019 were as follows: (in thousands) September 30, 2020 December 31, 2019 Principal balance under First Lien Credit Agreement $ 682,883 $ 688,155 Less unamortized debt issuance costs and discounts (14,963 ) (17,233 ) $ 667,920 $ 670,922 Principal balance under Revolving Credit Facility 28,000 — $ 695,920 $ 670,922

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2020
Summary of Stock Option Activity	A summary of the stock option activity for the nine months ended September 30, 2020 is as follows, in thousands, except per share amounts and term information: Weighted Weighted Average Weighted Average Remaining Aggregate Average Exercise Contractual Intrinsic Grant Date Shares Price Term Value Fair Value Outstanding at December 31, 2019 16,850 3.82 8.2 years $ 35,043 Granted 5,597 6.20 $ 2.95 Exercised (467 ) 2.91 1,429 Expired / Cancelled / Forfeited (585 ) 4.15 Outstanding at March 31, 2020 21,395 4.46 8.5 years 51,026 Granted 3,541 6.84 $ 3.17 Exercised (222 ) 2.39 926 Expired / Cancelled / Forfeited (673 ) 5.13 Outstanding at June 30, 2020 24,041 4.81 8.4 years 47,750 Granted 881 33.00 $ 16.60 Exercised (1,233 ) 3.48 22,960 Expired / Cancelled / Forfeited (125 ) 5.21 Outstanding at September 30, 2020 23,564 5.93 8.4 years 1,169,173 Exercisable at September 30, 2020 9,544 3.28 7.3 years 499,342
Assumptions Used in Black-Scholes Model to Determine Fair Value for Stock Option Awards Granted	All options outstanding at September 30, 2020 are options to purchase shares of Class A Common Stock. The fair value of option awards issued with service and performance vesting conditions are estimated on the grant date using the Black-Scholes option pricing model. The following table summarizes the assumptions used: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Risk-free interest rate 0.4% 1.4% - 1.6% 0.4% - 1.4% 1.4% - 2.4% Expected term 5.8 - 6.0 years 5.6 - 6.3 years 5.3 - 6.3 years 5.6 - 6.3 years Expected stock price volatility 55% 50% 50% - 62% 50% Dividend yield — — — — Fair value of common stock per share $33.00 $3.88 - $4.69 $5.94 - $33.00 $2.75 - $4.69
Restricted Stock
Summary of Restricted Stock Activity	The following table summarizes Restricted Stock activity for the three and nine months ended September 30, 2020: Restricted Restricted Stock Units for Class A Restricted Stock Units for Class B Weighted Average Stock Common Common Grant Date (in thousands, except per share amounts) Awards Stock Stock Fair Value Nonvested restricted shares at December 31, 2019 1,879 — — $ 3.88 Granted — — — — Vested — — — — Nonvested restricted shares at March 31, 2020 1,879 — — 3.88 Granted — — — — Vested (470 ) — — 3.88 Nonvested restricted shares at June 30, 2020 1,409 — — 3.88 Granted — 948 24,633 22.07 Vested — (1 ) — 33.00 Nonvested restricted shares at September 30, 2020 1,409 947 24,633 21.12

Basic and Diluted Earnings Pe_2

Basic and Diluted Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Schedule Computation of Earnings (Loss) Per Share	The computation of earnings (loss) per share for the three and nine months ended September 30, 2020 and 2019 is as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands, except per share data) 2020 2019 2020 2019 Numerator: Net (loss) income $ (50,032 ) $ 19,619 $ 4,651 $ 50,821 Less: Undistributed earnings allocated to convertible preferred stock — (7,003 ) (1,606 ) (18,183 ) Net (loss) income attributable to common stockholders - basic $ (50,032 ) $ 12,616 $ 3,045 $ 32,638 Add: Undistributed earnings reallocated to holders of common stock — 92 47 220 Net (loss) income attributable to common stockholders - diluted $ (50,032 ) $ 12,708 $ 3,092 $ 32,858 Denominator: Weighted average shares - basic 241,061 227,058 233,727 226,251 Dilutive impact of stock options and restricted stock awards — 4,712 10,802 4,308 Weighted average shares - diluted 241,061 231,770 244,529 230,559 (Loss) earnings per share Basic $ (0.21 ) $ 0.06 $ 0.01 $ 0.14 Diluted $ (0.21 ) $ 0.05 $ 0.01 $ 0.14
Weighted-Average Potentially Dilutive Shares Were Excluded From Computation of Diluted Net (Loss) Income Per Share	The following weighted-average potentially dilutive shares were excluded from the computation of diluted net (loss) income per share for the periods presented because including them would have been antidilutive: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2020 2019 2020 2019 Redeemable convertible preferred stock 117,825 126,046 123,285 126,046 Stock options and restricted stock awards 30,537 8,654 7,540 7,503

Description of Business - Addit

Description of Business - Additional Information (Details) - USD ($)	Sep. 25, 2020	Sep. 24, 2020	Sep. 30, 2020	Sep. 30, 2020	Sep. 13, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Oct. 07, 2015
Description Of Business [Line Items]
Entity incorporation month and year				2015-09
Proceeds from issuance of common stock in initial public offering, net of underwriting discounts and commissions				$ 891,793,000
Redeemable convertible preferred stock carrying value								$ 737,009,000
Preferred stock, shares authorized		50,000,000	50,000,000	50,000,000				0
Preferred stock, par value		$ 0.0001	$ 0.0001	$ 0.0001				$ 0.0001
Percentage of aggregate outstanding shares of common stock to be cease				10.00%
Common stock conversion term				Each share of Class B Common Stock is convertible into one share of Class A Common Stock at any time at the option of the holder and will automatically convert to Class A Common Stock upon any transfer, except for certain permitted transfers. All Class B Common Stock will convert automatically into an equivalent number of Class A Common Stock upon the earlier of (i) September 25, 2027; and (ii) the first date the aggregate number of shares of Class B Common Stock cease to represent at least 10% of the aggregate outstanding shares of common stock.
Common Class A
Description Of Business [Line Items]
Common stock, par value		$ 0.0001	$ 0.0001	$ 0.0001				$ 0.0001
Common stock, shares authorized		2,000,000,000	2,000,000,000	2,000,000,000				0
Conversion of stock, shares converted		10,098,121
Common stock voting rights				one vote per share
Redeemable Convertible Preferred Stock
Description Of Business [Line Items]
Redeemable convertible preferred stock converted into common stock		126,045,531	126,046,000
Redeemable convertible preferred stock carrying value		$ 737,000,000				$ 737,009,000	$ 737,009,000	$ 737,009,000	$ 737,009,000	$ 737,009,000	$ 737,009,000	$ 737,009,000
Common Class B
Description Of Business [Line Items]
Common stock, par value		$ 0.0001	$ 0.0001	$ 0.0001				$ 0.0001
Common stock, shares authorized		1,000,000,000	1,000,000,000	1,000,000,000				0
Conversion of stock, shares converted		357,265,256
Common stock voting rights				10 votes per share
Initial Public Offering
Description Of Business [Line Items]
Sale of stock, description of transaction				The Company’s registration statement on Form S-1 (“IPO Registration Statement”) related to its initial public offering (“IPO”) was declared effective on September 22, 2020, and the Company’s Class A common stock began trading on the Nasdaq Global Select Market on September 23, 2020.
Sale of stock, transaction date				Sep. 25, 2020
Number of aggregate shares sold by existing stockholders	11,192,657
Proceeds from issuance of common stock in initial public offering, net of underwriting discounts and commissions	$ 886,900,000
Underwriting discounts and commissions	52,500,000
Other offering expenses	$ 4,900,000
Stock issuance costs unpaid				$ 3,100,000
Initial Public Offering | Common Class A
Description Of Business [Line Items]
Stock issued during period	39,807,691
Common stock, par value	$ 0.0001
Offering price per share	$ 33
Initial Public Offering | Class A and Class B Common Stock
Description Of Business [Line Items]
Stock issued during period	28,615,034		28,615,000
Underwriters’ Option to Purchase Additional Shares
Description Of Business [Line Items]
Stock issued during period	5,192,307
Private Placement | Common Class A
Description Of Business [Line Items]
Stock issued during period	3,030,303		3,030,000
Stock purchase agreement, authorized amount					$ 100,000,000
GoodRx, Inc.
Description Of Business [Line Items]
Percentage of outstanding shares acquired													100.00%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details)	3 Months Ended						9 Months Ended		12 Months Ended
	Sep. 30, 2020USD ($)Customer	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)	Sep. 30, 2019USD ($)Customer	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Sep. 30, 2020USD ($)segmentCustomer	Sep. 30, 2019USD ($)Customer	Dec. 31, 2019USD ($)Customer	Dec. 31, 2018USD ($)
Accounting Policies [Line Items]
Total revenue	$ 140,453,000			$ 101,745,000			$ 397,156,000	$ 274,968,000
Net loss	(50,032,000)	$ 27,337,000	$ 27,346,000	19,619,000	$ 19,650,000	$ 11,552,000	4,651,000	50,821,000
Total assets	1,546,805,000						1,546,805,000		$ 386,796,000
Total liabilities	790,396,000						790,396,000		737,369,000
Total stockholders’ deficit	756,409,000	$ (1,026,735,000)	$ (1,057,043,000)	(1,104,351,000)	$ (1,127,394,000)	$ (1,149,724,000)	$ 756,409,000	(1,104,351,000)	(1,087,582,000)	$ (1,162,427,000)
Number of operating segments | segment							1
Comprehensive income (loss)	$ 0			$ 0			$ 0	$ 0
Accounting standards update [Extensible List]							us-gaap:AccountingStandardsUpdate201813Member
Change in accounting principle accounting standards update adoption date	Jan. 1, 2020						Jan. 1, 2020
Change in accounting principle, accounting standards update, immaterial effect [true false]	true						true
Change in accounting principle, accounting standards update, adopted [true false]	true						true
Money Market Funds | Fair Value, Inputs, Level 1
Accounting Policies [Line Items]
Cash equivalents, fair value disclosure	$ 1,013,500,000						$ 1,013,500,000		$ 0
Customer Concentration Risk | Revenue From Customer
Accounting Policies [Line Items]
Number of customers | Customer	4			2			3	2
Customer Concentration Risk | Revenue From Customer | Customer One
Accounting Policies [Line Items]
Concentration risk percentage	16.00%			25.00%			17.00%	25.00%
Customer Concentration Risk | Revenue From Customer | Customer Two
Accounting Policies [Line Items]
Concentration risk percentage	13.00%			24.00%			16.00%	23.00%
Customer Concentration Risk | Revenue From Customer | Customer Three
Accounting Policies [Line Items]
Concentration risk percentage	12.00%						11.00%
Customer Concentration Risk | Revenue From Customer | Customer Four
Accounting Policies [Line Items]
Concentration risk percentage	10.00%
Credit Concentration Risk | Accounts Receivable
Accounting Policies [Line Items]
Number of customers | Customer							2		2
Credit Concentration Risk | Accounts Receivable | Customer One
Accounting Policies [Line Items]
Concentration risk percentage							12.00%		17.00%
Credit Concentration Risk | Accounts Receivable | Customer Two
Accounting Policies [Line Items]
Concentration risk percentage							11.00%		16.00%
Variable Interest Entity
Accounting Policies [Line Items]
Total revenue	$ 3,000,000			$ 400,000			$ 6,600,000	$ 600,000
Net loss	(300,000)			$ (400,000)			(900,000)	$ (900,000)
Total assets	4,800,000						4,800,000		$ 1,400,000
Total liabilities	7,300,000						7,300,000		2,900,000
Total stockholders’ deficit	$ (2,500,000)						$ (2,500,000)		$ (1,500,000)

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Accounting Policies [Line Items]
Revenue	$ 140,453	$ 101,745	$ 397,156	$ 274,968
Prescription Transactions Revenue
Accounting Policies [Line Items]
Revenue	124,385	95,795	356,950	260,114
Other Revenue
Accounting Policies [Line Items]
Revenue	$ 16,068	$ 5,950	$ 40,206	$ 14,854

Business Combinations - Additio

Business Combinations - Additional Information (Details) $ in Thousands	Aug. 30, 2019USD ($)	Apr. 18, 2019USD ($)	Aug. 31, 2020USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2019USD ($)
Business Acquisition [Line Items]
Goodwill				$ 261,116	$ 236,225
Scriptcycle LLC
Business Acquisition [Line Items]
Date of acquisition			Aug. 31, 2020
Business combination, aggregate consideration			$ 58,300
Estimated fair value of contingent consideration			800	$ 1,700
Contingent consideration based on achievement of certain revenue thresholds			2,900
Goodwill			24,900
Identifiable intangible assets related to acquisition			28,300
Acquired current assets			5,900
Assumed liabilities			1,100
Scriptcycle LLC | Customer Related Intangible Assets
Business Acquisition [Line Items]
Identifiable intangible assets related to acquisition			$ 25,300
Identifiable intangible assets estimated useful life			11 years
Scriptcycle LLC | Developed Technology and Tradename
Business Acquisition [Line Items]
Identifiable intangible assets related to acquisition			$ 3,000
Scriptcycle LLC | Developed Technology and Tradename | Minimum
Business Acquisition [Line Items]
Identifiable intangible assets estimated useful life			1 year
Scriptcycle LLC | Developed Technology and Tradename | Maximum
Business Acquisition [Line Items]
Identifiable intangible assets estimated useful life			9 years
Scriptcycle LLC | Measurement Input, Discount Rate
Business Acquisition [Line Items]
Business combination consideration discounted rate			5.4	5.3
Sappira Inc.
Business Acquisition [Line Items]
Date of acquisition		Apr. 18, 2019
Business combination, aggregate consideration		$ 14,300
Identifiable intangible assets related to acquisition		4,200
Acquired current assets		$ 2,100
Percentage of outstanding shares acquired		100.00%
Consideration placed in escrow for potential breaches		$ 1,400
Assumed current liabilities		500
Sappira Inc. | Developed Technology
Business Acquisition [Line Items]
Identifiable intangible assets related to acquisition		$ 3,100
Identifiable intangible assets estimated useful life		4 years
Sappira Inc. | Trademarks and Backlog
Business Acquisition [Line Items]
Identifiable intangible assets related to acquisition		$ 1,100
Sappira Inc. | Trademarks and Backlog | Minimum
Business Acquisition [Line Items]
Identifiable intangible assets estimated useful life		1 year
Sappira Inc. | Trademarks and Backlog | Maximum
Business Acquisition [Line Items]
Identifiable intangible assets estimated useful life		7 years
FocusScript LLC
Business Acquisition [Line Items]
Date of acquisition	Aug. 30, 2019
Business combination, aggregate consideration	$ 18,700
FocusScript LLC | Developed Technology
Business Acquisition [Line Items]
Identifiable intangible assets related to acquisition	$ 12,200
Identifiable intangible assets estimated useful life	4 years

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Prepaid Expense And Other Assets Current [Abstract]
Income taxes receivable	$ 28,759
Prepaid expenses	8,169	$ 5,014
Lease incentive receivable	2,702	7,389
Total prepaid expenses and other current assets	$ 39,630	$ 12,403

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Payables And Accruals [Abstract]
Accrued bonus and payroll	$ 12,908	$ 3,037
Accrued marketing	11,372	5,820
Deferred revenue	6,911	3,453
Income taxes payable		1,349
Other accrued expenses	4,902	1,897
Total accrued expenses and other current liabilities	$ 36,093	$ 15,556

Accrued Expenses and Other Cu_4

Accrued Expenses and Other Current Liabilities - Additional Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Payables And Accruals [Abstract]
Deferred revenue	$ 6,911	$ 3,453
Revenue recognized	$ 3,300

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	Mar. 27, 2020	Mar. 26, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income tax rate			26.30%	22.60%	(112.80%)	21.90%
Federal statutory rate			21.00%		21.00%
Interest expense deduction percentage of adjusted taxable income, CARES Act	50.00%	30.00%
Reduction in deferred tax assets, CARES Act			$ 0		$ 2,300,000
Reduction in income taxes payable, CARES Act			0		2,300,000
Changes in unrecognized tax benefits						$ 0
Unrecognized tax benefits			$ 0		$ 0

Debt - Schedule of Debt (Detail

Debt - Schedule of Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Total debt	$ 695,920	$ 670,922
Revolving Credit Facility
Debt Instrument [Line Items]
Principal balance	28,000
First Lien Credit Agreement
Debt Instrument [Line Items]
Principal balance	682,883	688,155
Less unamortized debt issuance costs and discounts	(14,963)	(17,233)
Total debt	$ 667,920	$ 670,922

Debt - Additional Information (

Debt - Additional Information (Details) - USD ($)	1 Months Ended
	May 31, 2020	Mar. 31, 2020	Apr. 30, 2020
First Lien Credit Agreement
Debt Instrument [Line Items]
Line of credit	$ 100,000,000		$ 60,000,000
Line of credit maturity date	Oct. 11, 2024
First Lien Credit Agreement | Other Assets
Debt Instrument [Line Items]
Lender and third-party costs	$ 1,300,000
First Lien Credit Agreement | Minimum
Debt Instrument [Line Items]
Interest rate on used amounts	2.50%
Interest rate on unused amounts	0.25%
First Lien Credit Agreement | Maximum
Debt Instrument [Line Items]
Interest rate on used amounts	3.00%
Interest rate on unused amounts	0.50%
Revolving Credit Facility
Debt Instrument [Line Items]
Proceeds from line of credit		$ 28,000,000

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended			9 Months Ended	12 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted Average Exercise Prices, granted	$ 33
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares outstanding, Beginning balance	24,041	21,395	16,850	16,850
Granted, shares	881	3,541	5,597
Exercised, shares	(1,233)	(222)	(467)
Expired / Cancelled / Forfeited, shares	(125)	(673)	(585)
Shares outstanding, Ending Balance	23,564	24,041	21,395	23,564	16,850
Exercisable at September 30, 2020	9,544			9,544
Weighted Average Exercise Prices, Beginning balance	$ 4.81	$ 4.46	$ 3.82	$ 3.82
Weighted Average Exercise Prices, granted	33	6.84	6.20
Weighted Average Exercise Prices, Exercised	3.48	2.39	2.91
Weighted Average Exercise Prices, Expired/ Cancelled/ Forfeited	5.21	5.13	4.15
Weighted Average Exercise Prices, Ending balance	5.93	$ 4.81	$ 4.46	5.93	$ 3.82
Weighted Average Exercise Prices, Exercisable at September 30, 2020	$ 3.28			$ 3.28
Weighted average remaining contractual term, Outstanding	8 years 4 months 24 days	8 years 4 months 24 days	8 years 6 months		8 years 2 months 12 days
Aggregate Intrinsic Value, Outstanding	$ 47,750	$ 51,026			$ 35,043
Aggregate Intrinsic Value, Exercisable	22,960	926	$ 1,429
Aggregate Intrinsic Value, Outstanding	1,169,173	$ 47,750	$ 51,026	$ 1,169,173
Aggregate Intrinsic Value, Exercisable	$ 499,342			$ 499,342
Weighted Average Grant Date Fair Value, Granted	$ 16.60	$ 3.17	$ 2.95

Stock-Based Compensation - Assu

Stock-Based Compensation - Assumptions Used in Black-Scholes Model to Determine Fair Value for Stock Option Awards Granted (Details) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	0.40%
Risk-free interest rate, minimum		1.40%	0.40%	1.40%
Risk-free interest rate, maximum		1.60%	1.40%	2.40%
Expected stock price volatility	55.00%	50.00%		50.00%
Expected stock price volatility, minimum			50.00%
Expected stock price volatility, maximum			62.00%
Fair value of common stock per share	$ 33
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	5 years 9 months 18 days	5 years 7 months 6 days	5 years 3 months 18 days	5 years 7 months 6 days
Fair value of common stock per share		$ 3.88	$ 5.94	$ 2.75
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	6 years	6 years 3 months 18 days	6 years 3 months 18 days	6 years 3 months 18 days
Fair value of common stock per share		$ 4.69	$ 33	$ 4.69

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	Sep. 11, 2020	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense				$ 6.8			$ 0.7	$ 10.2	$ 2.1
Unrecognized stock-based compensation cost		$ 40.2		40.2				$ 40.2
Weighted-average period over which cost is expected to be recognized								3 years 3 months 18 days
Option to purchase shares of common stock			400,000
Fair value of option			$ 2.4
Performance and Marked Based Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense				0.3
Stock options granted to purchase of common stock			600,000
Exercise price of common stock			$ 6.84
Estimated grant date fair value			$ 1.4
Performance and Marked Based Stock Options | Purchase Price, One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted to purchase of common stock			200,000
Stock options to purchase common stock, per share			$ 17.82		$ 17.82
Performance and Marked Based Stock Options | Purchase Price, Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted to purchase of common stock			200,000
Stock options to purchase common stock, per share			$ 23.76		23.76
Performance and Marked Based Stock Options | Purchase Price, Three
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted to purchase of common stock			200,000
Stock options to purchase common stock, per share			$ 29.70		$ 29.70
Performance and Marked Based Stock Options | Satisfied Monthly Over 4-year
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted to purchase of common stock			400,000
Vesting period			4 years
Performance and Marked Based Stock Options | Satisfied on January 1, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted to purchase of common stock			200,000
Stock options vesting date			Jan. 1, 2022
Restricted Stock Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense				0.5			$ 0.3	$ 1.4	$ 0.6
Weighted-average period over which cost is expected to be recognized								2 years 7 months 6 days
Unrecognized stock-based compensation cost		$ 4.6		$ 4.6				$ 4.6
Aggregate shares of common stock granted				0	0	0
Shares vested				0	470,000	0
Restricted Stock Units for Class A Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense				$ 1.6				$ 1.6
Weighted-average period over which cost is expected to be recognized								3 years 10 months 24 days
Vesting period		4 years
Unrecognized stock-based compensation cost		$ 29.7		$ 29.7				$ 29.7
Aggregate shares of common stock granted				948,000	0	0
Shares vested				1,000	0	0
Restricted Stock Units ("RSUs")
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense				$ 98.1
Weighted-average period over which cost is expected to be recognized	1 year 2 months 12 days
Unrecognized compensation cost	$ 533.3	$ 435.2		435.2				$ 435.2
Restricted Stock Units ("RSUs") | Co-Chief Executive Officers
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Aggregate shares of common stock granted	24,633,066
Restricted Stock Units ("RSUs") Performance-Vesting Founders Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense				87.7
Restricted Stock Units ("RSUs") Performance-Vesting Founders Awards | Co-Chief Executive Officers
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares vested	8,211,022
Restricted Stock Units ("RSUs") Performance-Vesting Founders Awards | Co-Chief Executive Officers | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options to purchase common stock, per share	$ 6.07
Restricted Stock Units ("RSUs") Performance-Vesting Founders Awards | Co-Chief Executive Officers | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options to purchase common stock, per share	$ 51.28
Restricted Stock Units ("RSUs") Time-Vesting Founders Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense				$ 10.4
Restricted Stock Units ("RSUs") Time-Vesting Founders Awards | Co-Chief Executive Officers
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years
Shares vested	4,105,511

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Restricted Stock Activity (Details) - $ / shares shares in Thousands	3 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Restricted Stock Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Nonvested restricted shares, Beginning Balance	1,409	1,879	1,879
Granted	0	0	0
Vested	0	(470)	0
Nonvested restricted shares, Ending Balance	1,409	1,409	1,879
Restricted Stock Units for Class A Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Nonvested restricted shares, Beginning Balance	0	0	0
Granted	948	0	0
Vested	(1)	0	0
Nonvested restricted shares, Ending Balance	947	0	0
Restricted Stock Units for Class B Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Nonvested restricted shares, Beginning Balance	0	0	0
Granted	24,633	0	0
Vested	0	0	0
Nonvested restricted shares, Ending Balance	24,633	0	0
Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Nonvested restricted shares , Weighted Average Grant Date Fair Value, Beginning Balance	$ 3.88	$ 3.88	$ 3.88
Granted, Weighted Average Grant Date Fair Value	22.07	0	0
Vested, Weighted Average Grant Date Fair Value	33	3.88	0
Nonvested restricted shares , Weighted Average Grant Date Fair Value, Ending Balance	$ 21.12	$ 3.88	$ 3.88

Basic and Diluted Earnings Pe_3

Basic and Diluted Earnings Per Share - Schedule Computation of Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Numerator:
Net income (loss)	$ (50,032)	$ 27,337	$ 27,346	$ 19,619	$ 19,650	$ 11,552	$ 4,651	$ 50,821
Less: Undistributed earnings allocated to convertible preferred stock				(7,003)			(1,606)	(18,183)
Net (loss) income attributable to common stockholders - basic	(50,032)			12,616			3,045	32,638
Add: Undistributed earnings reallocated to holders of common stock				92			47	220
Net (loss) income attributable to common stockholders - diluted	$ (50,032)			$ 12,708			$ 3,092	$ 32,858
Denominator:
Basic	241,061			227,058			233,727	226,251
Dilutive impact of stock options and restricted stock awards				4,712			10,802	4,308
Weighted average shares - diluted	241,061			231,770			244,529	230,559
(Loss) earnings per share:
(Loss) earnings per share - basic	$ (0.21)			$ 0.06			$ 0.01	$ 0.14
(Loss) earnings per share - diluted	$ (0.21)			$ 0.05			$ 0.01	$ 0.14

Basic and Diluted Earnings Pe_4

Basic and Diluted Earnings Per Share - Weighted-Average Potentially Dilutive Shares Were Excluded From Computation of Diluted Net (Loss) Income Per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Stock Options and Restricted Stock Awards
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Weighted-average potentially dilutive shares were excluded from computation of diluted net (loss) income per share	30,537	8,654	7,540	7,503
Redeemable Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Weighted-average potentially dilutive shares were excluded from computation of diluted net (loss) income per share	117,825	126,046	123,285	126,046

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($) $ in Millions	Oct. 22, 2020	Sep. 11, 2020	Oct. 31, 2020	Dec. 31, 2020
Restricted Stock Units ("RSUs")
Subsequent Event [Line Items]
Weighted-average period over which cost is expected to be recognized		1 year 2 months 12 days
Restricted Stock Units ("RSUs") | Forecast
Subsequent Event [Line Items]
Acceleration of share-based compensation expense				$ 232.1
Subsequent Event | Restricted Stock Units ("RSUs")
Subsequent Event [Line Items]
Number of shares vested	16,422,044
Subsequent Event | Restricted Stock Units ("RSUs") | Board of Directors
Subsequent Event [Line Items]
Vesting period			4 years
Estimated grant date fair value			$ 60.9
Weighted-average period over which cost is expected to be recognized			4 years
Subsequent Event | Restricted Stock Units ("RSUs") | Common Class A | Board of Directors
Subsequent Event [Line Items]
Number of shares granted			1,300,000
Subsequent Event | Revolving Credit Facility
Subsequent Event [Line Items]
Repayments of outstanding balance			$ 28